GlobalData provides unique and market-leading data and insights into the respiratory market. Browse or search our Report Store for the latest comprehensive reports, market data, analysis and survey findings alongside industry information on key companies, markets and financial deals.

Cystic Fibrosis – Global Clinical Trials Review, H2, 2021

  • $2,500
  • December 2021
GlobalData's clinical trial report, “Cystic Fibrosis - Global Clinical Trials Review, H2, 2021" provides an overview of Cystic Fibrosis Clinical trials scenario. This report provides top line data relating to...

Malignant Pleural Effusion – Global Clinical Trials Review, H2, 2021

  • $2,500
  • October 2021
GlobalData's clinical trial report, “Malignant Pleural Effusion - Global Clinical Trials Review, H2, 2021" provides an overview of Malignant Pleural Effusion Clinical trials scenario. This report provides top line data...

Pulmonary Fibrosis – Global Clinical Trials Review, H2, 2021

  • $2,500
  • October 2021
GlobalData's clinical trial report, “Pulmonary Fibrosis - Global Clinical Trials Review, H2, 2021" provides an overview of Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to...

Obstructive Sleep Apnea – Global Clinical Trials Review, H2, 2021

  • $2,500
  • September 2021
GlobalData's clinical trial report, “Obstructive Sleep Apnea - Global Clinical Trials Review, H2, 2021" provides an overview of Obstructive Sleep Apnea Clinical trials scenario. This report provides top line data...

Cystic Fibrosis (CF) – Epidemiology Forecast to 2030

  • $3,995
  • August 2021
Cystic fibrosis (CF) is a progressive, inherited disorder that primarily affects the respiratory and digestive systems. In people with CF, mucus, sweat, and other fluids produced in these systems are...

Cystic Fibrosis – Global Drug Forecast and Market Analysis to 2030

  • $10,995
  • August 2021
The cystic fibrosis (CF) market is expected to grow from $8.2bn in 2020 to $12.7bn in 2030 in the seven major markets (7MM*) at a compound annual growth rate (CAGR)...

Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 (Event Driven Update)

  • $10,995
  • April 2021
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis...

Malignant Pleural Effusion – Global Clinical Trials Review, H1, 2021

  • $2,500
  • April 2021
GlobalData's clinical trial report, “Malignant Pleural Effusion - Global Clinical Trials Review, H1, 2021" provides an overview of Malignant Pleural Effusion Clinical trials scenario. This report provides top line data...

Pulmonary Fibrosis – Global Clinical Trials Review, H1, 2021

  • $2,500
  • April 2021
GlobalData's clinical trial report, “Pulmonary Fibrosis - Global Clinical Trials Review, H1, 2021" provides an overview of Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to...

Obstructive Sleep Apnea – Global Clinical Trials Review, H1, 2021

  • $2,500
  • March 2021
GlobalData's clinical trial report, “Obstructive Sleep Apnea - Global Clinical Trials Review, H1, 2021" provides an overview of Obstructive Sleep Apnea Clinical trials scenario. This report provides top line data...